Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies

The Lancet Diabetes and Endocrinology

Volumn 7, Issue 2, 2019, Pages 115-127

  Coresh, Josef ^a   Heerspink, Hiddo J L ^b   Sang, Yingying ^a   Matsushita, Kunihiro ^a   Arnlov, Johan ^c,d   Astor, Brad C ^e   Black, Corri ^f,g   Brunskill, Nigel J ^h,i   Carrero, Juan Jesus ^d   Feldman, Harold I ^j   Fox, Caroline S ^k,l   Inker, Lesley A ^m   Ishani, Areef ^n,o   Ito, Sadayoshi ^p,am   Jassal, Simerjot ^q   Konta, Tsuneo ^r   Polkinghorne, Kevan ^s,t   Romundstad, Solfrid ^u,v   Solbu, Marit D ^w,x   Stempniewicz, Nikita ^y   Stengel, Benedicte ^z,aa,ab   Tonelli, Marcello ^ac   Umesawa, Mitsumasa ^ad,ae   Waikar, Sushrut S ^l   Wen, Chi Pang ^af,ag   Wetzels, Jack F M ^ah   Woodward, Mark ^a,ai,aj   Grams, Morgan E ^a   Kovesdy, Csaba P ^ak,al   Levey, Andrew S ^m   Gansevoort, Ron T ^b   Appel, Lawrence J ^am   Greene, Tom ^am   Chen, Teresa K ^am   Chalmers, John ^am   Arima, Hisatomi ^am   Perkovic, Vlado ^am   Levin, Adeera ^am   Djurdjev, Ognjenka ^am   Tang, Mila ^am   Nally, Joseph ^am   Navaneethan, Sankar D ^am   Schold, Jesse D ^am   Weldegiorgis, Misghina ^am   Herrington, William G ^am   Smith, Margaret ^am   Hsu, C Yenchih ^am   Hwang, Shih Jen ^am   Chang, Alex R ^am   Kirchner, H Lester ^am   Green, Jamie A ^am   Ho, Kevin ^am   Marks, Angharad ^am   Prescott, Gordon ^am   Clark, Laura E ^am   Fluck, Nick ^am   Shalev, Varda ^am   Chodick, Gabriel ^am   Blankestijn, Peter J ^am   Van Zuilen, Arjan ^am   Van den Brand, Jan A ^am   Sarnak, Mark J ^am   Bottinger, Erwin ^am   Nadkarni, Girish N ^am   Ellis, Stephen G ^am   Nadukuru, Rajiv ^am   Metzger, Marie ^am   Flamant, Martin ^am   Houillier, Pascal ^am   Haymann, Jean Philippe ^am   Froissart, Marc ^am   Kenealy, Timothy ^am   Elley, Raina C ^am   Collins, John F ^am   Drury, Paul L ^am   Cuddeback, John K ^am   Ciemins, Elizabeth L ^am   Stempniewicz, Rich ^am   Nelson, Robert G ^am   Knowler, William C ^am   Bakker, Stephen J ^am   Major, Rupert W ^am   Medcalf, James F ^am   Shepherd, David ^am   Barrett Connor, Elizabeth ^am   Bergstrom, Jaclyn ^am   Ix, Joachim H ^am   Molnar, Miklos Z ^am   Sumida, Keiichi ^am   de Zeeuw, Dick ^am   Brenner, Barry ^am   Qureshi, Abdul R ^am   Elinder, Carl Gustaf ^am   Runesson, Bjorn ^am   Evans, Marie ^am   Segelmark, Marten ^am   Stendahl, Maria ^am   Schön, Staffan ^am   Naimark, David M ^am   Tangri, Navdeep ^am   Sud, Maneesh ^am   Hirayama, Atsushi ^am   Ichikawa, Kazunobu ^am   Bilo, Henk JG ^am   Landman, Gijs WD ^am   Van Hateren, Kornelis JJ ^am   Kleefstra, Nanne ^am   Hallan, Stein I ^am   Ballew, Shoshana H ^am   Chen, Jingsha ^am   Kwak, Lucia ^am   Surapaneni, Aditya ^am   Parving, Hans Henrik ^am   Rodby, Roger A ^am   Rohde, Richard D ^am   Lewis, Julia B ^am   Lewis, Edmund ^am   Perrone, Ronald D ^am   Abebe, Kaleab Z ^am   Hou, Fan F ^am   Xie, Di ^am   Hunsicker, Lawrence G ^am   Imai, Enyu ^am   Kobayashi, Fumiaki ^am   Makino, Hirofumi ^am   Remuzzi, Giuseppe ^am   Ruggenenti, Piero ^am   Eckardt, Kai Uwe ^am   Gudmundsdottir, Hrefna ^am   Maciulaitis, Romaldas ^am   Manley, Tom ^am   Smith, Kimberly ^am   Stockbridge, Norman ^am   Thompson, Aliza ^am   Vetter, Thorsten ^am   Willis, Kerry ^am   Zhang, Luxia ^am   more..

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c DALARNA UNIVERSITY   (Sweden)

^d KAROLINSKA INSTITUTE   (Sweden)

^e UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^f UNIVERSITY OF ABERDEEN   (United Kingdom)

^g NHS GRAMPIAN   (United Kingdom)

^h UNIVERSITY OF LEICESTER   (United Kingdom)

ⁱ UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST   (United Kingdom)

^j UNIVERSITY OF PENNSYLVANIA   (United States)

^k FRAMINGHAM HEART STUDY   (United States)

^l BRIGHAM AND WOMEN S HOSPITAL   (United States)

^m TUFTS MEDICAL CENTER   (United States)

ⁿ Veterans Administration Health Care System   (United States)

^o UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^p TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^q UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^r YAMAGATA UNIVERSITY   (Japan)

^s MONASH MEDICAL CENTRE   (Australia)

^t MONASH UNIVERSITY   (Australia)

^u NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^v Levanger Hospital   (Norway)

^w UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^x UNIVERSITY OF TROMSØ   (Norway)

^y American Medical Group Association   (United States)

^z CENTRE FOR RESEARCH IN EPIDEMIOLOGY AND POPULATION HEALTH   (France)

^aa LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^ab UNIVERSITÉ PARIS SACLAY   (France)

^ac UNIVERSITY OF CALGARY   (Canada)

^ad DOKKYO MEDICAL UNIVERSITY   (Japan)

^ae Ibaraki Health Service Association   (Japan)

^af CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^ag NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^ah RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^ai UNIVERSITY OF OXFORD   (United Kingdom)

^aj UNIVERSITY OF NEW SOUTH WALES   (Australia)

^ak UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^al VETERANS AFFAIRS MEDICAL CENTER   (United States)

^am NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CREATININE; PROTEIN;

ALBUMINURIA; ARTICLE; CONFIDENCE INTERVAL; CREATININE BLOOD LEVEL; CREATININE URINE LEVEL; DATA ANALYSIS; DIABETES MELLITUS; END STAGE RENAL DISEASE; ESTIMATED GLOMERULAR FILTRATION RATE; FOLLOW UP; HAZARD RATIO; HUMAN; INFORMATION PROCESSING; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROTEIN URINE LEVEL; RENAL REPLACEMENT THERAPY; RISK FACTOR; SEX DIFFERENCE; CHRONIC KIDNEY FAILURE; COMPLICATION; DISEASE EXACERBATION; GLOMERULUS FILTRATION RATE; KIDNEY FUNCTION TEST; META ANALYSIS; OBSERVATIONAL STUDY; PATHOLOGY; PATHOPHYSIOLOGY;

ALBUMINURIA; DISEASE PROGRESSION; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; OBSERVATIONAL STUDIES AS TOPIC; PROGNOSIS; RISK FACTORS;

EID: 85060314551     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(18)30313-9     Document Type: Article

References (34)

1. Parving, HH, Andersen, AR, Smidt, UM, Friisberg, B, Svendsen, PA, Reduced albuminuria during early and aggressive antihypertensive treatment of insulin-dependent diabetic patients with diabetic nephropathy. Diabetes Care 4 (1981), 459–463.
2. de Zeeuw, D, Should albuminuria be a therapeutic target in patients with hypertension and diabetes?. Am J Hypertens 17 (2004), 11S–15S.
3. Levey, AS, Inker, LA, Matsushita, K, et al. GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am J Kidney Dis 64 (2014), 821–835.
4. Heerspink, HJL, Kröpelin, TF, Hoekman, J, de Zeeuw, D, Drug-induced reduction in albuminuria is associated with subsequent renoprotection: a meta-analysis. J Am Soc Nephrol 26 (2015), 2055–2064.
5. Heerspink, HJL, Greene, T, Tighiouart, H, et al. Change in albuminuria as a surrogate endpoint for kidney disease progression in clinical trials: a meta-analysis of treatment effects of 41 randomized trials. Lancet Diabetes Endocrinol, 2019 published online Jan 8. http://dx.doi.org/10.1016/S2213-8587(18)30314-0.
6. Inker, LA, Levey, AS, Pandya, K, Stoycheff, N, Okparavero, A, Greene, T, on behalf of the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI). Early change in proteinuria as a surrogate end point for kidney disease progression: an individual patient meta-analysis. Am J Kidney Dis 64 (2014), 74–85.
7. Inker, LA, Mondal, H, Greene, T, et al. Early change in urine protein as a surrogate end point in studies of IgA nephropathy: an individual-patient meta-analysis. Am J Kidney Dis 68 (2016), 392–401.
8. Thompson, A, Proteinuria as a surrogate end point—more data are needed. Nat Rev Nephrol 8 (2012), 306–309.
9. Cravedi, P, Ruggenenti, P, Remuzzi, G, Proteinuria should be used as a surrogate in CKD. Nat Rev Nephrol 8 (2012), 301–306.
10. Lambers Heerspink, HJ, Gansevoort, RT, Albuminuria is an appropriate therapeutic target in patients with CKD: the pro view. Clin J Am Soc Nephrol 10 (2015), 1079–1088.
11. Fried, LF, Lewis, J, Albuminuria is not an appropriate therapeutic target in patients with CKD: the con view. Clin J Am Soc Nephrol 10 (2015), 1089–1093.
12. Carrero, JJ, Grams, ME, Sang, Y, et al. Albuminuria changes are associated with subsequent risk of end-stage renal disease and mortality. Kidney Int 91 (2017), 244–251.
13. Sumida, K, Molnar, MZ, Potukuchi, PK, et al. Changes in albuminuria and subsequent risk of incident kidney disease. Clin J Am Soc Nephrol 12 (2017), 1941–1949.
14. Usui, T, Kanda, E, Iseki, C, Iseki, K, Kashihara, N, Nangaku, M, Observation period for changes in proteinuria and risk prediction of end-stage renal disease in general population. Nephrology (Carlton) 23 (2018), 821–829.
15. Schmieder, RE, Mann, JF, Schumacher, H, et al. Changes in albuminuria predict mortality and morbidity in patients with vascular disease. J Am Soc Nephrol 22 (2011), 1353–1364.
16. Brantsma, AH, Bakker, SJ, de Zeeuw, D, de Jong, PE, Gansevoort, RT, for the PREVEND Study Group. Extended prognostic value of urinary albumin excretion for cardiovascular events. J Am Soc Nephrol 19 (2008), 1785–1791.
17. Smith, M, Herrington, WG, Weldegiorgis, M, Hobbs, FR, Bankhead, C, Woodward, M, Change in albuminuria and risk of renal cardiovascular outcomes: natural variaition should be taken into account. Kidney Int Rep 3 (2018), 939–949.
18. Witte, EC, Lambers Heerspink, HJ, de Zeeuw, D, Bakker, SJ, de Jong, PE, Gansevoort, R, First morning voids are more reliable than spot urine samples to assess microalbuminuria. J Am Soc Nephrol 20 (2009), 436–443.
19. Chronic Kidney Disease Prognosis Consortium. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 375 (2010), 2073–2081.
20. van der Velde, M, Matsushita, K, Coresh, J, et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney Int 79 (2011), 1341–1352.
21. Gansevoort, RT, Matsushita, K, van der Velde, M, et al. Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes. A collaborative meta-analysis of general and high-risk population cohorts. Kidney Int 80 (2011), 93–104.
22. Astor, BC, Matsushita, K, Gansevoort, RT, et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. Kidney Int 79 (2011), 1331–1340.
23. Matsushita, K, Mahmoodi, BK, Woodward, M, et al. Comparison of risk prediction using the CKD-EPI equation and the MDRD study equation for estimated glomerular filtration rate. JAMA 307 (2012), 1941–1951.
24. Miller, WG, Bruns, DE, Hortin, GL, et al. Current issues in measurement and reporting of urinary albumin excretion. Clin Chem 55 (2009), 24–38.
25. Levey, AS, Stevens, LA, Schmid, CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 150 (2009), 604–612.
26. Levey, AS, Coresh, J, Greene, T, et al. Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem 53 (2007), 766–772.
27. Carroll, RJ, Ruppert, D, Stefanski, LA, Crainiceanu, CM, Measurement error in nonlinear models: a modern perspective. 2nd edn., 2006, Chapman and Hall/CRC, Taylor & Francis Group, Boca Raton.
28. Grams, ME, Coresh, J, Segev, DL, Kucirka, LM, Tighiouart, H, Sarnak, MJ, Vascular disease, ESRD, and death: interpreting competing risk analyses. Clin J Am Soc Nephrol 7 (2012), 1606–1614.
29. Qaseem, A, Hopkins, RH Jr, Sweet, DE, Starkey, M, Shekelle, P, Screening, monitoring, and treatment of stage 1 to 3 chronic kidney disease: a clinical practice guideline from the American College of Physicians. Ann Intern Med 159 (2013), 835–847.
30. Eijkelkamp, WB, Zhang, Z, Remuzzi, G, et al. Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. J Am Soc Nephrol 18 (2007), 1540–1546.
31. Lea, J, Greene, T, Hebert, L, et al. The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension. Arch Intern Med 165 (2005), 947–953.
32. Jun, M, Ohkuma, T, Zoungas, S, et al. Changes in albuminuria and the risk of major clinical outcomes in diabetes: results from ADVANCE-ON. Diabetes Care 41 (2018), 163–170.
33. Parving, HH, Brenner, BM, McMurray, JJ, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 367 (2012), 2204–2213.
34. Tangri, N, Grams, ME, Levey, AS, et al. Multinational assessment of accuracy of equations for predicting risk of kidney failure: a meta-analysis. JAMA 315 (2016), 164–174.